Metabolic enzyme |
CYP3A5 |
*1/*1 |
High metabolic activity, low
transport activity |
Rupatadine |
45 |
|
|
*1/*3 |
Low metabolic activity, high transport activity |
|
45 |
|
CYP3A4 |
*2 |
May lead to drug-drug interaction |
Cimetidine |
47 |
|
|
*7 |
|
|
|
|
|
*16 |
|
|
|
|
|
*18;−392A>G (rs2740574) |
|
|
|
|
CYP2J2 |
*8(G312R) |
Affects the structure of P450 heme |
Terfenadine |
55 |
|
|
*9(P351L)
|
No effects
No effects
|
|
|
|
|
*10(P115L) |
|
|
|
|
CYP2D6
|
*1,*2
|
Extensive metabolizers
|
Asmiranzapine
Mirtazapine
Methiazine
|
60,
63-65
|
|
|
*3~*6 |
Poor metabolizers |
|
|
|
|
*10,*41 |
Intermediate metabolizers |
|
|
|
|
(CYP2D6*1)xN
(CYP2D6*2)xN”
|
Ultrarapid metabolizers
|
|
|
Transport molecules |
ABCB1 |
1236C>T,2677G>A/T, 3435C>T |
Contradictory results |
Fexofenadine |
75,
76 |
|
SLCO
|
2B1
(SLCO2B1c.[1457C>T]
)
|
Reduced transport function
|
Fexofenadine
|
82
83
|
|
|
1B1 |
Not reported |
|
|
|
|
1B3 |
|
|
|
Receptors |
HRH1 |
CT, TT |
Increase the incidence of AR and affect the
curative effect |
|
85 |
|
|
rs901865 G/G |
Increase sleepiness |
Desloratadine |
103 |
|
HRH4 |
rs77041280(TA+TT) |
Reduce the efficacy of H1A orally |
|
84 |
|
|
rs77485247(TA+AA) |
|
|
|